• Farmagen
    Clinical Research
    Center

Farmagen reliable solution partner in bioavailability / bioequivalence studies

Clinical UPDATES

Rector of Gaziantep University (GAÜN) Dr. Ali Gür explained that the drug imported from abroad for the use of patients in the treatment of COVID19 can be developed and introduced to the market with a trial initiated by Gaziantep University with the partnership of Farmagen GCP Center and Novagenix Bioanalytical Drug R&D Center. Rector Professor emphasized that the clinical trial of this drug's bioequivalence study will be performed by Farmagen, one of the GAÜN Technopark companies. Dr. Ali Gür later shared the following information: "The active ingredient in this drug is now being used effectively in the treatment of Covid-19 disease, which has been declared as a pandemic by our Ministry of Health and the World Health Organization. Our studies on Bioavailability and Bioequivalence, with the approval of the Ministry of Health, Medicines and Medical Devices Agency, the leading of Project Resposible GAÜN Faculty Member. Prof. Dr. Muradiye Nacak and Project Manager Prof. Dr. Aydın Erenmişoğlu, with a large project team, started the trail with taking all special protective measures. Gaziantep University Technopark has made us proud as the solution partner of the Domestic Pharmaceutical Industry in this critical period and continues its activities at full speed during these critical epidemic days."

Rector of Gaziantep University Dr. Ali Gür, in his statement that there are a few other drugs that are used in the treatment of COVID-19 and whose legal authorization processes are underway to conduct bioequivalence studies for national production in our country, and that these processes will be shared with the public as they are completed, said, “This will contribute to the domestic pharmaceutical industry and the national economy in critical epidemic days. We would like to thank firstly our Technopark firm, our technicians, our partner stakeholders and everyone who contributed to this trial.”

Bioequivalence studies of ritonavir/lopinavir and favipravir molecules have been successfully completed in Farmagen, which is the only BE & BA clinical center that can still actively work with isolation procedure due to COVID-19 pandemic in our country and one of the few centers in the world. Bioanalytical studies have been carried out at Novagenix Bioanalytical R&D Center without interruption and continues by competing against time. In this way, it will be possible to supply these drugs, which have problems in their supply and have high costs, very cheaply.

The umifenovir tablet bioequivalence study will begin in a very short time and the favipravir equivalent candidates developed by our other domestic manufacturers are waiting in line.

Thank you to our partners and the officials who did not withhold their support.

Clinical Research

What is Clinical Trials and Why it is done?

Most clinical trials are done to show whether the use of a new drug or medical device is effective and safe in humans.

Read more »

What is Good Clinical Practices (GCP)?

It is a Standard for designing, performing, implementing, monitoring, auditing, recording, analyzing and reporting clinical trials...

Read more »

Why Clinical Trials are Important?

In order for new drugs and other treatment methods to be beneficial to humans, they must be tested before they are widely used.

Read more »

PERSONAL DATA PROTECTION

  • PDR Information

    PDR Application Form

  • Contact

    • Address: Gaziantep Üniversitesi Teknoloji Geliştirme Bölgesi (Teknopark) Burç; Yolu 27000 Şahinbey GAZİANTEP - TURKEY

    • Phone: +90 342 360 62 62

    • Mobile: +90 533 257 60 70 - +90 537 023 08 06

    • E-mail: info@farmagenarge.com

    • Fax: 0(342) 360 6457

    Follow us